SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

FATE

Fate Therapeutics, Inc.
BULLISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The data are early but de-risk the FT836 program and validate the Sword & Shield platform in solid tumors without conditioning chemo, a key differentiator. However, with only 2 efficacy-evaluable patients showing activity, the stock may see a modest positive move on proof-of-concept but faces binary risk from future enrollment expansion and durability data. Monitor for next data update and potential partnership interest.

DirectionBullish
Confidencemedium
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.74
T+0 close · Jun 1, 2026 · via day close
Latest settled
−6.93%
T+60 · $2.55
Vs SPY
−8.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $2.74entry
  2. T+1 · 6mo ago −6.20%α −6.35% · $2.57
  3. T+5 · 5mo ago −27.74%α −24.99% · $1.98
  4. T+20 · 5mo ago −1.46%α −0.16% · $2.70
  5. T+60 · 3mo ago −6.93%α −8.17% · $2.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid tumors, at ASCO 2026. In two heavily pre-treated KRASwt metastatic colorectal cancer patients, FT836 plus cetuximab without conditioning chemotherapy showed a 19% tumor reduction (Case 1) and a 52% liver lesion reduction (Case 2), with no DLTs, CRS, ICANS, or GvHD across nine patients. The data demonstrate first-in-human proof of trafficking and persistence in tumor tissue without lymphodepletion, but the sample is tiny (n=9 safety, n=5 efficacy-evaluable, n=2 with anti-tumor activity) and early-stage, limiting immediate stock-moving impact.

Key Facts

  • FT836 is an off-the-shelf, iPSC-derived CAR T-cell targeting MICA/B with Sword & Shield technology to eliminate need for conditioning chemotherapy.
  • Nine patients enrolled across two regimens (FT836 + cetuximab, n=6; FT836 + trastuzumab, n=3); no DLTs, CRS, ICANS, or GvHD observed.
  • Five patients available for efficacy; two KRASwt mCRC patients with 7 prior lines each showed tumor reduction: 19% sum-of-diameters (Case 1) and 52% liver lesion reduction (Case 2).
  • FT836 detected in peripheral blood (peak Day 4) and tumor tissue (Day 22 biopsy) without conditioning chemotherapy, with evidence of tumor immune microenvironment remodeling.
  • Company plans to focus on CRC patient population based on these results.
  • Market cap ~$331M; analyst consensus 61% bullish (11 Buy, 7 Hold).

Financial Impact

No financial data provided; early-stage clinical data with no revenue or guidance impact.

Risk Factors

  • Extremely small sample size (n=2 efficacy-evaluable with anti-tumor activity); results may not replicate in larger cohorts.
  • No conditioning chemotherapy may limit CAR T persistence in broader patient populations; durability data are immature.
  • Company is pre-revenue with no approved products; cash runway and financing risk remain.
  • Competitive landscape includes multiple off-the-shelf CAR T and bispecific approaches in solid tumors.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304368

Track record

21 reports on FATE

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026